Lapatinib PharOS 250 mg, filmomhulde tabletten Holland - hollandsk - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

lapatinib pharos 250 mg, filmomhulde tabletten

lapatinibditosilaat 1-water 405 mg/stuk samenstelling overeenkomend met ; lapatinib 250 mg/stuk - filmomhulde tablet - cellulose, microkristallijn (e 460(i)) ; hypromellose, type 2910 (3 - 15 mpa.s) (e 464) ; ijzeroxide geel (e 172) ; macrogol 400 ; magnesiumstearaat (e 470b) ; natriumzetmeelglycolaat ; polysorbaat 80 (e 433) ; povidon k 30 (e 1201) ; titaandioxide (e 171), cellulose, microkristallijn (e 460) ; hypromellose, type 2910 (3 - 15 mpa.s) (e 464) ; ijzeroxide geel (e 172) ; macrogol 400 ; magnesiumstearaat (e 470b) ; natriumzetmeelglycolaat ; polysorbaat 80 (e 433) ; povidon k 30 (e 1201) ; titaandioxide (e 171)

Teriflunomide Mylan Den Europæiske Union - hollandsk - EMA (European Medicines Agency)

teriflunomide mylan

mylan pharmaceuticals limited - teriflunomide - multiple sclerose, relapsing-remitting - immunosuppressiva - teriflunomide mylan is indicated for the treatment of adult patients and paediatric patients aged 10 years and older (body weight > 40 kg) with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 of the smpc for important information on the population for which efficacy has been established).

Teriflunomide Accord Den Europæiske Union - hollandsk - EMA (European Medicines Agency)

teriflunomide accord

accord healthcare s.l.u. - teriflunomide - multiple sclerose, relapsing-remitting - immunosuppressivum, selectieve immunosuppressiva - teriflunomide accord is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).

Teriflunomide Sandoz 14 mg, filmomhulde tabletten Holland - hollandsk - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

teriflunomide sandoz 14 mg, filmomhulde tabletten

teriflunomide 14 mg/stuk - filmomhulde tablet - allurarood ac aluminium lak (e 129) ; briljantblauw fcf aluminiumlak (e133) ; cellulose, microkristallijn (e 460(i)) ; glycerol (e 422) ; hyprolose (e 463) ; hypromellose, type 2910 (3 - 15 mpa.s) (e 464) ; indigokarmijn aluminiumlak (e 132) ; lactose 1-water ; magnesiumstearaat (e 470b) ; maÏszetmeel ; natriumzetmeelglycolaat ; siliciumdioxide (e 551) ; talk (e 553 b) ; titaandioxide (e 171), allurarood ac aluminium lak (e 129) ; briljantblauw fcf aluminiumlak (e133) ; cellulose, microkristallijn (e 460) ; glycerol (e 422) ; hyprolose (e 463) ; hypromellose, type 2910 (3 - 15 mpa.s) (e 464) ; indigokarmijn aluminiumlak (e 132) ; lactose 1-water ; magnesiumstearaat (e 470b) ; maÏszetmeel ; natriumzetmeelglycolaat ; siliciumdioxide (e 551) ; talk (e 553 b) ; titaandioxide (e 171)

Vafseo Den Europæiske Union - hollandsk - EMA (European Medicines Agency)

vafseo

akebia europe limited - vadadustat - renal insufficiency, chronic; anemia - antianemische preparaten - vafseo is indicated for the treatment of symptomatic anaemia associated with chronic kidney disease (ckd) in adults on chronic maintenance dialysis.